Mayela Rodríguez-Violante, Ana J Hernández-Medrano, Amin Cervantes-Arriaga, Cesarina Torres-Vásquez, Dioselina Tristán-Samaniego, Carolina Zepeda-Salazar, Victoria Cerino-Palomino, Arturo Abundes-Corona
Monotherapy is the recommended initial treatment for early Parkinson's disease. The pharmacological options for initial treatment include dopaminergic agonists, monoamine oxidase B inhibitors, and levodopa formulations. Several factors should be considered when selecting the optimal treatment, such as disease severity, disease duration, age, activity level, and the risk of developing motor and non-motor complications. Early evidence on the potential role of levodopa formulations in the risk of dyskinesia led to levodopa aversion in the late 1990s and early 2000s, favoring the use of levodopa-sparing options like dopamine agonists...
July 17, 2024: Revista de Investigación Clínica; Organo del Hospital de Enfermedades de la Nutrición